The Food and Drug Administration has granted interventional device developer Boston Scientific expedited review status for its Taxus paclitaxel-eluting coronary stent system. Granting of expedited review status means that the application is designated to receive priority review before other pending applications.
In its notification letter to the company, the FDA stated that the product might represent "a breakthrough technology," which offers an alternative to current FDA-approved technologies for treating coronary artery disease, according to the Natick, MA-based firm.
By AuntMinnie.com staff writers
March 13, 2003
Related Reading
Boston Scientific submits stent for PMA, February 25, 2003
Boston Scientific posts preliminary 2002 numbers, gets CE Mark, January 22, 2003
Cordis files suit against Boston Scientific, January 15, 2003
Boston Scientific, TriVascular form alliance, January 14, 2003
Boston Scientific biliary stent approved, October 30, 2002
Copyright © 2003 AuntMinnie.com
